Advertisement

Diabetologia

, Volume 33, Issue 12, pp 713–718 | Cite as

An immunomodulating protein, Ling Zhi-8 (LZ-8) prevents insulitis in non-obese diabetic mice

  • K. Kino
  • K. Mizumoto
  • T. Sone
  • T. Yamaji
  • J. Watanabe
  • A. Yamashita
  • K. Yamaoka
  • K. Shimizu
  • K. Ko
  • H. Tsunoo
Originals

Summary

Ling Zhi-8 (LZ-8), a novel and recently discovered immunomodulatory protein having in vivo immunosuppressive activity, was tested for in vivo effect against Type 1 (insulin-dependent) diabetes mellitus in the non-obese diabetic mouse, the disease having immunologically mediated aetiology in this animal. LZ-8 had mitogenic activity in vitro towards spleen cells of the non-obese diabetic mice as previously shown towards those of DBA/2 mice. Intraperitoneal administration of LZ-8 twice weekly into the mice (10.3–12.6 mg/kg body weight) from 4 weeks of age prevented insulitis and an almost normal number of insulin producing cells were observed. Extreme insulitis and reduction of the number of insulin producing cells were observed in the pancreata of the untreated non-obese diabetic mouse. No cumulative incidence of diabetes mellitus was observed in the LZ-8 treated group, while cumulative incidences of 70% and 60% were observed in an untreated group followed up to 42 weeks of age when the incidence of diabetes was defined as a plasma glucose level of greater than 11 mmol/l and as a urine glucose level of greater than 2 +, respectively. T cell subset population analysis was performed to further investigate the action of LZ-8 on the non-obese diabetic mouse which revealed that LZ-8 treatment increased in L3T4+/Lyt-2+ ratio.

Key words

LZ-8 immunomodulator NOD mouse Type 1 (insulin-dependent) diabetes insulitis autoimmunity T cell subset 

References

  1. 1.
    Kino K, Yamashita A, Yamaoka K, Watanabe J, Tanaka S, Ko K, Shimizu K, Tsunoo H (1989) Isolation and characterization of a new immunomodulatory protein, Ling Zhi-8 (LZ-8), from Ganoderma lucidum. J Biol Chem 264: 472–478PubMedGoogle Scholar
  2. 2.
    Tanaka S, Ko K, Kino K, Tsuchiya K, Yamashita A, Murasugi A, Sakuma S, Tsunoo H (1989) Complete amino acid sequence of an immunomodulatory protein, Ling Zhi-8 (LZ-8): an immunomodulator from a fungus, Ganoderma lucidum having similarity to immunoglobulin variable regions. J Biol Chem 264: 16372–16377PubMedGoogle Scholar
  3. 3.
    Makino S, Kunimoto K, Muraoka Y, Mizushima Y, Katagiri K, Tochino Y (1980) Breeding of a non-obese, diabetic strain of mice. Exp Anim 29: 1–13Google Scholar
  4. 4.
    Fujita T, Yui R, Kusumoto Y, Serizawa Y, Makino S, Tochino Y (1982) Lymphocyte insulitis in a ‘non-obese diabetic (NOD)’ strain of mice: an immunohistochemical and electron microscope investigation. Biomed Res 3: 429–443Google Scholar
  5. 5.
    Miyazaki A, Hanafusa T, Yamada K, Miyagawa J, Fujino-Kurihara H, Nakajima H, Nonaka K, Tarui S (1985) Predominance of T lymphocytes in pancreatic islets and spleen of pre-diabetic non-obese diabetic (NOD) mice: a longitudinal study. Clin Exp Immunol 60: 622–630PubMedGoogle Scholar
  6. 6.
    Koike T, Itoh Y, Ishii T, Ito I, Takabayashi K, Maruyama N, Tomioka H, Yoshida S (1987) Preventive effect of monoclonal anti-L3T4 antibody on development of diabetes in NOD mice. Diabetes 36: 539–541PubMedGoogle Scholar
  7. 7.
    Wang Y, Hao L, Gill RG, Lafferty KJ (1987) Autoimmune diabetes in NOD mouse is L3T4 T-lymphocyte dependent. Diabetes 36: 535–538PubMedGoogle Scholar
  8. 8.
    Harada M, Makino S (1986) Suppression of overt diabetes in NOD mice by anti-thymocyte serum or anti-Thy 1.2 antibody. Exp Anim 35: 501–504Google Scholar
  9. 9.
    Harada M (1987) Immune disturbance and pathogenesis of non-obese diabetes-prone (NOD) mice. Exp Clin Endocrinol 89: 251–258PubMedGoogle Scholar
  10. 10.
    Makino S, Harada Y, Kishimoto Y, Hayashi Y (1986) Absence of insulitis and overt diabetes in athymic nude mice with NOD genetic background. Exp Anim 35: 495–498Google Scholar
  11. 11.
    Miller BJ, Appel MC, O'Neil JJ, Wicker LS (1988) Both the Lyt-2+ and L3T4+ T cell subsets are required for the transfer of diabetes in non-obese diabetic mice. J Immunol 140: 52–58PubMedGoogle Scholar
  12. 12.
    Bendelac A, Carnaud C, Boitard C, Bach JF (1987) Syngeneic transfer of autoimmune diabetes from diabetic NOD mice to healthy neonates: Requirement for both L3T4+ and Lyt-2+ cells. J Exp Med 166: 823–832CrossRefPubMedGoogle Scholar
  13. 13.
    Wicker LS, Miller BJ, Mullen Y (1986) Transfer of autoimmune diabetes mellitus with splenocytes from nonobese diabetic (NOD) mice. Diabetes 35: 855–860PubMedGoogle Scholar
  14. 14.
    Kanazawa Y, Komeda K, Sato S, Mori S, Akanuma K, Takaku F (1984) Non-obese-diabetic mice: immune mechanisms of pancreatic B-cell destruction. Diabetologia 27: 113–115CrossRefPubMedGoogle Scholar
  15. 15.
    Toyota T, Satoh J, Oya K, Shintani S, Okano T (1986) Streptococcal preparation (OK-432) inhibits development of Type I diabetes in NOD mice. Diabetes 35: 496–499PubMedGoogle Scholar
  16. 16.
    Lee KU, Amano K, Yoon JW (1988) Evidence for inital involvement of macrophage in development of insulitis in NOD mice. Diabetes 37: 989–991PubMedGoogle Scholar
  17. 17.
    Charlton B, Bacelj A, Mandel TE (1988) Administration of silica particles or anti-Lyt2 antibody prevents B-cell destruction in NOD mice given cyclophosphamide. Diabetes 37: 930–935PubMedGoogle Scholar
  18. 18.
    Kataoka S, Satoh J, Fujiya H, Toyota T, Suzuki R, Itoh K, Kumagai K (1983) Immunological aspects of the non-obese diabetic (NOD) mouse: abnormalities of cellular immunity. Diabetes 32: 247–253PubMedGoogle Scholar
  19. 19.
    Achea-Orbea H, McDevitt HO (1987) The first external domain of the nonobese diabetic mouse class II I-A B chain is unique. Proc Natl Acad Sci USA 84: 2435–2439PubMedGoogle Scholar
  20. 20.
    Hattori M, Buse JB, Jackson RA, Glimcher L, Dorf ME, Minami M, Makino S, Moriwaki K, Kazuya H, Strauss WM, Seidman JG, Eisenbarth GS (1986) The NOD mouse: recessive diabetogenic gene in the major histocompatibility complex. Science 231: 733–735PubMedGoogle Scholar
  21. 21.
    Strong DM, Ahmed AA, Thurman GB, Sell KW (1973) In vitro stimulation of murine spleen cells using a microculture system and a multiple automated sample harvester. J Immunol Methods 2: 279–291CrossRefPubMedGoogle Scholar
  22. 22.
    Hsu SM, Raine L, Fanger H (1981) Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 29: 577–580PubMedGoogle Scholar
  23. 23.
    Kino K, Mizumoto K, Watanabe J, Tsunoo H (1987) Immunohistochemical studies on hemoglobin-haptoglobin and hemoglobin catabolism sites. J Histochem Cytochem 35: 381–386PubMedGoogle Scholar
  24. 24.
    Mori Y, Suko M, Okudaira H, Matsuba I, Tsuruoka A, Sasaki A, Yokoyama H, Tanase T, Shida T, Nishimura M, Terada E, Ikeda Y (1986) Preventive effects of cyclosporin on diabetes in NOD mice. Diabetologia 29: 244–247PubMedGoogle Scholar
  25. 25.
    Shevach EM (1985) The effects of cyclosporin A on the immune system. Ann Rev Immunol 3: 397–423CrossRefGoogle Scholar
  26. 26.
    Torisu M, Katano M, Kimura Y, Itoh H, Takasue M (1983) New approach to management of malignant ascites with a streptococcal preparation, OK-432. I. Improvement of host immunity and prolongation of survival. Surgery 93: 357–364PubMedGoogle Scholar
  27. 27.
    Watanabe Y, Iwa T (1984) Clinical value of immunotherapy for lung cancer by the streptococcal preparation OK-432. Cancer 53: 248–253PubMedGoogle Scholar
  28. 28.
    Tadakuma T, Pierce CW (1976) Site of action of a soluble immune response suppressor (SIRS) produced by concanavalin A-activated spleen cells. J Immunol 117: 967–972PubMedGoogle Scholar
  29. 29.
    Kaufman DB, Carnard C, Stach JL, Bach JF (1976) The suppressive effect of a supernate from concanavalin A-activated lymphocytes. Cell Immunol 47: 153–162Google Scholar
  30. 30.
    Formby B, Miller N, Peterson CM (1988) Adoptive immunotherapy of diabetes in autologous nonobese diabetic mice with lymphoid cells ex vivo exposed to cyclosporin plus interleukin 2. Diabetes 37: 1305–1309PubMedGoogle Scholar
  31. 31.
    Rossini AA, Mordes JP, Like A (1985) Immunology of insulin-dependent diabetes mellitus. Ann Rev Immunol 3: 289–320CrossRefGoogle Scholar
  32. 32.
    Krakauer RS, Waldmann TA, Strober W (1976) Loss of suppressor T cells in adult NZB/NZW mice. J Exp Med 144: 662–673CrossRefGoogle Scholar
  33. 33.
    Almawi WA, Dolphin PJ, Thies RL, McMaster WR, Levy JG, Pope BL (1988) Suppressor cell-inducing factor: A new lymphokine secreted by a natural suppressor cell line with natural cytotoxic activity I: purification to apparent homogeneity and initial characterization of suppressor cell-inducing factor. J Immunol 141: 2529–2535PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1990

Authors and Affiliations

  • K. Kino
    • 1
  • K. Mizumoto
    • 1
  • T. Sone
    • 1
  • T. Yamaji
    • 1
  • J. Watanabe
    • 1
  • A. Yamashita
    • 1
  • K. Yamaoka
    • 1
  • K. Shimizu
    • 1
  • K. Ko
    • 1
  • H. Tsunoo
    • 1
  1. 1.Biochemical Genetics DivisionMeiji Institute of Health ScienceOdawaraJapan

Personalised recommendations